A new analysis, designed to shed light on the benefits of SGLT2 inhibition in patients who have heart failure with preserved ejection fraction (HFpEF), shows that dapagliflozin (Farxiga; AstraZeneca) ...
Cardiovascular disease remains a leading global cause of death, and we break down its pathology, risk factors, and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback